par Schöffski, Patrick;Garcia, Jorge A;Stadler, Walter M;Gil, Thierry 
;Jonasch, Eric;Tagawa, Scott T;Smitt, Melanie;Yang, Xin ;Oliner, Kelly S;Anderson, Abraham;Zhu, Minghua;Kabbinavar, Fairooz
Référence BJU international, 108, 5, page (679-686)
Publication Publié, 2011-09
;Jonasch, Eric;Tagawa, Scott T;Smitt, Melanie;Yang, Xin ;Oliner, Kelly S;Anderson, Abraham;Zhu, Minghua;Kabbinavar, FairoozRéférence BJU international, 108, 5, page (679-686)
Publication Publié, 2011-09
Article révisé par les pairs
| Titre: |
|
| Auteur: | Schöffski, Patrick; Garcia, Jorge A; Stadler, Walter M; Gil, Thierry; Jonasch, Eric; Tagawa, Scott T; Smitt, Melanie; Yang, Xin; Oliner, Kelly S; Anderson, Abraham; Zhu, Minghua; Kabbinavar, Fairooz |
| Informations sur la publication: | BJU international, 108, 5, page (679-686) |
| Statut de publication: | Publié, 2011-09 |
| Sujet CREF: | Cancérologie |
| Mots-clés: | AMG 102 |
| c-Met | |
| clear cell renal cell carcinoma | |
| hepatocyte growth factor | |
| papillary renal cell carcinoma | |
| renal cell carcinoma | |
| MeSH keywords: | Adult |
| Aged | |
| Aged, 80 and over | |
| Antibodies, Monoclonal -- administration & dosage -- adverse effects -- therapeutic use | |
| Antineoplastic Agents -- administration & dosage -- adverse effects -- therapeutic use | |
| Carcinoma, Renal Cell -- drug therapy -- mortality -- secondary | |
| Dose-Response Relationship, Drug | |
| Female | |
| Hepatocyte Growth Factor -- blood | |
| Humans | |
| Infusions, Intravenous | |
| Kidney Neoplasms -- drug therapy -- mortality -- secondary | |
| Male | |
| Middle Aged | |
| Survival Analysis | |
| Treatment Outcome | |
| Tumor Markers, Biological -- blood | |
| Note générale: | Clinical Trial, Phase II |
| Journal Article | |
| Research Support, Non-U.S. Gov't | |
| FLWIN | |
| SCOPUS: ar.j | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:1464-4096 |
| info:doi/10.1111/j.1464-410X.2010.09947.x | |
| info:scp/80051991655 | |
| info:pmid/21156020 |
